NovaBridge Biosciences · NASDAQ:NBP
NovaBridge Biosciences — Investor Presentation (April 2026)
43 slides from NovaBridge Biosciences's investor presentation, Apr 7, 2026
Slide 1: Company Presentation April 2026
Company Presentation April 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by NovaBridge Biosciences (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewin
Slide 3: Company Overview & Highlights
Company Overview & Highlights
Slide 4: NovaBridge: Accelerating Access to Innovation
NovaBridge: Accelerating Access to Innovation Global biotech platform with a portfolio of potential first- and best-in-class programs Two lead assets with compelling clinical proof-of-concept supporting differentiated positioning Givastomig: CLDN18.2 × 4-1BB bispecific antibody demonstrating robust
Slide 5: Our Evolution to Pioneer the Next Frontier in Global Innovation
Notes: mAb = monoclonal antibody; bsAb = bispecific antibody; PoC = Proof of Concept; PD-L1 = programmed death-ligand 1; CLDN18.2 = Claudin18.2 Our Evolution to Pioneer the Next Frontier in Global Innovation Pivot & Focus Asset-based Model Clinical-stage China Biotech 1.0 Clinical-stage US Biotech 2
Slide 6: Our Platform-based Business Model
Notes: mAb = monoclonal antibody; bsAb = bispecific antibody; PD-L1 = programmed death-ligand 1; CLDN18.2 = Claudin 18.2 Driving Accelerated Development and Value Creation of Innovations in a Quality-oriented and Approach Our Platform-based Business Model Accelerate innovative asset development with
Slide 7: Givastomig also known as ABL111, ragistomig also known as ABL503 BMS agreed to manufacture,
Givastomig also known as ABL111, ragistomig also known as ABL503 BMS agreed to manufacture, supply and grant us a license to use nivolumab (OPDIVO®) in our Phase 1 trial to evaluate givastomig’s combination with nivolumab and mFOLFOX6 Trial conducted by TJ Biopharma, NCT04322006 Global rights, ex-Gr
Slide 8: Visionary and Seasoned Management Team
Visionary and Seasoned Management Team A seasoned management team composed of industry veterans with extensive regional and functional expertise Years of Industry Experience # 12 Wei Fu Director and Executive Chairman of our Board 25 Sean Fu PhD, MBA Chief Executive Officer Phillip Dennis MD, PhD Ch
Slide 9: Oncology Program Givastomig
Oncology Program Givastomig Claudin 18.2 X 4-1BB bsAb with Best-in-Class Potential
Slide 10: Gastric cancer burden and market opportunity
5th most common cancer , 4th leading cause of cancer mortality worldwide1 Over 60% of patients are diagnosed at an advanced or metastatic stage2 5-year survival rates are only ~7%2 Sung 2021; Markets include U.S., five E.U. countries, and Japan in 2025 based on Data Monitor Biomed Tracker The Ameri
Slide 11: Givastomig: Best-in-Class, First-in-Class Broad Potential
Revised from Nat Rev Clin Oncol. 2024 May;21(5):354-369 Notes: scFv = single chain Fragment-variable region; IgG1 = Immunoglobin G1; ADCC = antibody-dependent cell-mediated cytotoxicity; CDC = complement-dependent cytotoxicity; TME = tumor microenvironment; PFS = progression free survival; CLDN18.2
Slide 12: Givastomig Development Plan: Phase 1b Study Design
Notes: GEC = gastroesophageal cancer; GEJ = gastroesophageal junction; EAC = esophageal adenocarcinoma; mFOLFOX6 = standard of care chemotherapy regimen; nivo = nivolumab; Q2W = every two weeks; Giva = givastomig; ORR = objective response rate; PK = pharmacokinetic; PD = pharmacodynamic; BoR = best
Slide 13: Givastomig Combination Baseline Patient Characteristics
Feature(s) 8 mg/kg (n=27) Giva combo 12mg/kg (n=27) 12 mg/kg (n=27) 8 mg/kg or 12 mg/kg (n=54) Age Median (y) 64 58 61 Gender Male 63% 41% 52% Female 37% 59% 48% Race Asian 15% 11% 13% White 59% 63% 61% Black 7% 11% 9% NR 19% 15% 17% ECOG PS 0 52% 48% 50% 1 48% 52% 50% 2 0% 0% 0% NR 0% 0% 0% CLDN18.
Slide 14: Givastomig Phase 1b Response Rates
Cohort / Study: Givastomig Phase 1b Combination CHECKMATE-6493 SPOTLIGHT4 ILUSTRO6 8 mg/kg esc + exp (n=27) 12 mg/kg esc + exp (n=27) 8 & 12 mg/kg esc + exp (n=53) mFOLFOX6 / CapeOX + Nivo (n=789) mFOLFOX6 + Zolbe (n=283) Zolbe+Nivo+ Chemo (n=77) Efficacy-evaluable (n)1 26 26 52 71 ORR % (n) 77 (20/
Slide 15: Tumor shrinkage in subjects
Biomarker Key: PD-L1 CPS < 5 or CLDN18.2 < 75 51/52 Subjects Experienced Tumor Shrinkage Notes: Data cutoff as of December 2, 2025. PD-L1 = programmed death-ligand 1; CPS = combined positive score; CLDN = Claudin 18.2;; CLDN18.2 = Claudin 18.2; SD = stable disease; uPR = unconfirmed partial response
Slide 16: Rapid Responses That Deepen Over Time
Rapid Responses That Deepen Over Time Dose level 8 mg/kg (n=26)1 12 mg/kg (n=26)2 Median time to response (mo., Min, Max) 1.8 (1.3, 7.5) 2.5 (1.5, 5.4) PD-L1 CPS ≥ 1 1.8 (1.3, 7.5) 1.8 (1.5, 3.9) PD-L1 CPS < 1 5.7 (1.7, 5.7) 3.6 (1.9, 5.4) CLDN18.2 ≥ 75 1.9 (1.5, 5.7) 1.8 (1.7, 3.9) CLDN18.2 < 75 1.
Slide 17: Promising Progression Free Survival Data Observed
Phase 1b PFS in efficacy evaluable patients Based on patients in the dose escalation and dose expansion cohorts Cohort / Study: Givastomig Phase 1b Combination Study CHECKMATE-6492 SPOTLIGHT3 ILUSTRO4 8 mg/kg esc + exp (n=27) 12 mg/kg esc + exp (n=27) 8 & 12 mg/kg esc + exp (n=54) mFOLFOX6 / CapeOX
Slide 18: Efficacy Breakdown of Givastomig vs. Zolbetuximab
Givastomig is an investigational early-phase therapy. Information in the tables above is not intended to be a direct comparison to approved treatments. The comparisons in the tables above are not based on data from head-to-head trials. Differences in trial designs, patient groups, trial endpoints, s
Slide 19: Givastomig Safety: Comparable to Other 1L Combinations in GEC
Cohort/Study Givastomig Phase 1b Combination Study CHECKMATE-6491 SPOTLIGHT2 ILUSTRO3 8 mg/kg (n=27) 12 mg/kg (n=27) mFOLFOX6 / CapeOX + Nivo (n=782) mFOLFOX6 + Zolbe (n=279) Zolbe+Nivo+ Chemo (n=77) TEAE All Grades 100% 100% NA >99% 98.7% ≥ Grade 3 70% 70% NA 87% 66.2% TRAE any drug All Grades 100%
Slide 20: Givastomig Safety Profile Suitable for Combination in 1L Gastric Cancer
Janjigian 2021; The Lancet, Volume 398, Issue 10294, 27 – 40 Notes: TRAE = treatment emergent adverse event, ORR = objective response rate, PFS = progression free survival, OS = overall survival Givastomig is an investigational early-phase therapy. Information in the text above is not intended to be
Slide 21: Givastomig Demonstrated BIC/FIC Potential in 1L GEC
Shitara et al. 2026 Shitara et al. 2023; The Lancet, Volume 401, Issue 10389, 1655 – 1668 Notes: ORR = objective response rate, PFS = progression free survival, OS = overall survival, AE = adverse event; CPI = checkpoint inhibitor *Givastomig is an investigational early-phase therapy. Information in
Slide 22: Expansion Data Reinforces Givastomig's Best-in-Class Potential
Expansion Data Reinforces Givastomig's Best-in-Class Potential Robust efficacy, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg Responses observed across a wide range of PD-L1 and CLDN18.2 expression levels Durable responses with 16.9-month mPFS observed at 8 mg/kg Well tolerated i
Slide 23: Givastomig market opportunity
Markets include U.S., five E.U. countries, and Japan in 2025 based on Data Monitor Biomed Tracker, based on 1L treatment HER2-negative status of 78%. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER-2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cance
Slide 24: Visara, Inc. NovaBridge's 1st Spoke
Visara, Inc. NovaBridge’s 1st Spoke 23
Slide 25: Transaction Structure
Transaction Structure Visara, Inc. NovaBridge AffaMed ESOP 65% 30% 5% NovaBridge invested cash for 65% equity interest in Visara AffaMed contributed its rights and interests in VIS-101 for 30% of the equity interest in Visara The remaining 5% equity interest in Visara reserved for an ESOP VIS-101-re
Slide 26: VIS-101 – Purpose-Designed to be Best-in-Class for Retinal Vascular Diseases
VIS-101 – Purpose-Designed to be Best-in-Class for Retinal Vascular Diseases 25 Anti-Ang-2 Anti-VEGF-A Modified Fc Phase 2a wet AMD Update Safe and well-tolerated Rapid, robust, and durable treatment responses Mean BVCA > 10 ETDRS letters Mean CST 100-150 µm Potentially best in class durability: ~Tw
Slide 27: $15B Total Branded Anti-VEGF-A Market
$15B Total Branded Anti-VEGF-A Market1 DME Wet AMD RVO 20M+ 21M+ 16M+ More than 57M people affected globally2 Data source: 1. Ophthalmic Anti-VEGF Therapeutics Market Size & Share 2025 – 2034, published December 2025, 2. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26
Slide 28: Anti-VEGF Ophthalmology Market Growth Driven by Efficacy and Durability
Global revenue projected to grow to >$20B by 2030 Increased revenue correlates with improved durability Lucentis® Q4W Eylea® Q8W Revenue 2y from Launch $1.8B $2.8B Vabysmo® Q8-16W Eylea HD® Q8-16W $4.4B $1.5B VIS-101 $1B+* Early Data Support VIS-101’s Potential for Best-in-Class Durability Q8-24W+ A
Slide 29: VIS-101: Purpose-Designed to be Best-in-Class Dual VEGF-A X ANG-2 Inhibitor
Bispecific, Tetravalent design: increased binding sites and increased VEGF-A and ANG-2 affinity Optimized Fc region for shortened plasma half-life Humanized anti-VEGF-A mAb ~2X inhibitory activity Anti-Ang-2 inhibitory peptides (18mers) ~17X inhibitory activity, for class leading durability ~Half of
Slide 30: VIS-101: Phase 2a Study Overview
4 doses Up to 16 weeks Study Assessed Safety and Tolerability of VIS-101, Time to Retreatment After Loading Doses 6 mg (n=25) 3 mg (n=13) Monthly follow-up to Week 36 or retreatment Patient criteria: Aged 50-80 years with wet AMD (both treatment naïve and pre-treated) BCVA ETDRS letter score 78-19 C
Slide 31: Phase 2a Study Demographics Represent Wet AMD Patients
Baseline characteristics were similar between the 6mg and 3mg cohorts Patient Characteristics 6mg (N=25) 3mg (N=13) Total (N=38) Age (average), years 69.5 71.5 Sex, (n, %) Male 17 (68.0) 8 (61.5) 25 (65.8) Female 8 (32.0) 5 (38.5) 13 (34.2) Baseline BCVA (Letters) 54.7 52.3 53.9 Baseline CST (μm) 41
Slide 32: VIS-101 - Sustained BCVA and CST Improvements
(7/9) (7/11) (3/9) (5/11) * * (16 vs. 24 weeks post loading doses) (7/9) (7/11) (3/9) (5/11) * Source: nAMD China Phase 2a final raw dataset (tab BCVA001_1) – not final analysis Notes: *12 randomized, one patient in the 6mg naïve patient cohort dropped out after week 8 follow-up. #One patient did no
Slide 33: VIS-101 – Robust Efficacy, Best-in-Class Durability
Q12W VIS-101 (3 intravitreal injections) Faricimab 6mg (All Treatment Naïve) Treatment free Less loading doses Faricimab (4 intravitreal injections) Treatment Interval: 12-16 weeks Faricimab, Q16W (n=31) Ranibizumab, 0.5mg, Q4W (n=16) Faricimab, Q12W (n=24) Q16W 1.Cross trial comparison, Faricimab d
Slide 34: VIS-101 - Best-in-Class Durability Potential
Source: nAMD China Phase 2a final raw dataset (tab TREAT001_1) Faricimab Phase 3 data; 16 weeks after loading. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3
Slide 35: VIS-101 - Favorable Safety Profile with No Dose-Limiting Toxicity
Source: ASKG712-CT-I-1_Phase 1/2a Top Line Table 14.3.2.5, *2 events one with a grade change, System Organ Class/Preferred Term (SOC/PT) SOC/PT 3mg (N=13) n(%) E 6mg (N=25) n(%) E Total Treatment Related TEAE 0 2 ( 8 ) 4 Eye Disorder 0 2 ( 8 ) 4 Uveitis 0 1 ( 4 ) 3* Vitreous opacities 0 1 ( 4 ) 1 *U
Slide 36: VIS-101 – Purpose-Designed to be Best-in-Class; Next Steps
VIS-101 – Purpose-Designed to be Best-in-Class for Retinal Vascular Diseases 35 Anti-Ang-2 Anti-VEGF-A Modified Fc Phase 2a wet AMD Update Safe and well-tolerated Rapid, robust, and durable treatment responses Potentially best in class durability Next Steps: Phase 2b study expected to be initiated H
Slide 37: Other Oncology Programs
Other Oncology Programs Ragistomig Uliledlimab
Slide 38: Ragistomig: A Potential Next-Generation Immuno-oncology Backbone
ASCO 2024 poster Cancer Discovery 2022 Notes: The comparisons in the table above are not based on data from head-to-head trials and are not direct comparisons. Differences in trial designs, patient groups, trial endpoints, study sizes, and other factors may impact the comparisons. bsAb = bispecific
Slide 39: Uliledlimab: A Potential Best-in-Class CD73 Therapeutic
Patient disposition based on ASCO 2023 Poster from a cohort of 70 enrolled patients with unresectable/metastatic disease, including 67 efficacy evaluable and 64 patients who received at least one post baseline tumor assessment per iRECIST. Overall study (up to n=190) enrolled 5 cohorts (3 NSCLC sub-
Slide 40: Financial Overview and Upcoming Catalysts
Financial Overview and Upcoming Catalysts
Slide 41: Financial Overview
Financial Overview No outstanding debt Cash, cash equivalents & short-term investments To support planned operations $210.8 million1 Runway to Q4 2028 Unlevered balance sheet Represents consolidated cash balance of NovaBridge (including Visara) as of December 31, 2025
Slide 42: Near-term Catalysts
Notes: 1L = first line; GEA = Gastroesophageal adenocarcinoma, including gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; BTC = biliary tract cancer; PDAC = pancreatic ductal adenocarcinoma; NSCLC = non-small cell lung cancer; Wet AMD = wet age-related macular degener
Slide 43: Thank you
Thank you www.novabridge.com IR@novabridge.com
NovaBridge Biosciences — Investor Presentation (April 2026) on 6ix